Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 5/2016

01-05-2016 | Letter to the Editor

Reply to the letter by Takeshi Yamada et al. concerning “Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?”

Authors: Jun Zhou, Zhi Peng, Lin Shen

Published in: Journal of Gastroenterology | Issue 5/2016

Login to get access

Excerpt

To the editor: …
Literature
1.
Zhou J, Peng Z, Liu Y, et al. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. J Gastroenterol. 2015;50:955–61.CrossRefPubMed
2.
Oyama K, Fushida S, Tsukada T, et al. Evaluation of serum HER2-ECD levels in patients with gastric cancer. J Gastroenterol. 2015;50:41–5.CrossRefPubMed
3.
Lam L, McAndrew N, Yee M, et al. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012;1826:199–208.PubMedPubMedCentral
Metadata
Title
Reply to the letter by Takeshi Yamada et al. concerning “Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?”
Authors
Jun Zhou
Zhi Peng
Lin Shen
Publication date
01-05-2016
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 5/2016
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1185-1

Other articles of this Issue 5/2016

Journal of Gastroenterology 5/2016 Go to the issue

Erratum

Erratum to: Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy

Review

Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease

Review

Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience

Review

Host–virus interactions in hepatitis B and hepatitis C infection

Original Article—Alimentary Tract

Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras

Original Article—Liver, Pancreas, and Biliary Tract

Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits